NCT03765099 is a NA clinical trial of Animal-Assisted Interactions in Advanced Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

Who is sponsoring NCT03765099?

NCT03765099 is sponsored by Vanderbilt-Ingram Cancer Center.

What drugs are being tested in NCT03765099?

Interventions in NCT03765099: Animal-Assisted Interactions.

What condition does NCT03765099 study?

NCT03765099 studies Advanced Cancer, Relapsed Cancer, Refractory Cancer.

Is NCT03765099 still recruiting?

NCT03765099 is currently completed. Last updated 23 January 2023.

Last reviewed 2023-01-23 · How we verify

NCT03765099

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents

Completed NA Last updated 23 January 2023

What this trial tests

NA trial testing Animal-Assisted Interactions in Advanced Cancer in 70 participants. Completed in 31 December 2022.

Timeline

21 February 2019

Primary endpoint
31 December 2021

31 December 2022

Quick facts

Lead sponsor	Vanderbilt-Ingram Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	70
Start date	21 February 2019
Primary completion	31 December 2021
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

Animal-Assisted Interactions

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →
Relapsed Cancer — all drugs for Relapsed Cancer →
Refractory Cancer — all drugs for Refractory Cancer →

Sponsor

Vanderbilt-Ingram Cancer Center — full company profile →

Who can join

Adults 3 to 17, any sex, with Advanced Cancer or Relapsed Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the effects of animal-assisted interactions (AAI) on stress, anxiety, and quality of life in children with a life-threatening condition and their parents. It is anticipated to be a milestone in understanding the human-animal bond.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of Animal-Assisted Interaction on Anxiety in Children With Advanced Cancer and Their Caregivers.
Mahoney AB, Akard TF, Cowfer BA, Dietrich MS, et al · · 2024 · cited 8× · PMID 37751186 · DOI 10.1089/jpm.2023.0091
Animal-Assisted Interventions for Children with Advanced Cancer: Child and Parent Perceptions.
Cowfer BA, Akard TF, Gilmer MJ. · · 2021 · cited 5× · PMID 34927159 · DOI 10.1089/pmr.2021.0039

Verify or expand the search:

Other trials of Animal-Assisted Interactions

Trials testing the same drug.

NCT04310345 — Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents · NA · completed

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other Vanderbilt-Ingram Cancer Center trials

Trials by the same sponsor.

NCT06638398 — Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules · NA · active not recruiting
NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
NCT06105801 — EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing · Phase 4 · recruiting
NCT06399640 — Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03765099 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center
Last refreshed: 23 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03765099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing